Kedrion and Kamada partner up for anti-COVID-19 IgG product
Human plasma-derived product will be developed and manufactured utilizing Kamada’s proprietary IgG platform technology
Kamada and Kedrion Biopharma have agreed a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARs-COV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients, the plasma-focused biopharma firms said on Wednesday.
The IgG product will be developed and manufactured using Kamada’s proprietary IgG platform technology.
Under the terms of the agreement, Kamada will be responsible for product development, manufacturing, clinical development, with Kedrion’s support, and regulatory submissions.
Kedrion will provide plasma, collected at its KEDPLASMA centres, from donors who have recovered from the virus. Upon regulatory approval, it will be responsible for commercialization in the US, Europe, Australia, and South Korea.
Kamada will distribute the treatment in all territories outside of those Kedrion is responsible for and marketing rights for the product in China will be shared by both firms.
The collaboration will initially focus on providing the treatment to patients in Italy, Israel and the US through various clinical programmes, while expanding development and commercialization efforts to additional markets, the firms said.
“In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on developing and manufacturing a potentially safe and effective treatment,” said Paolo Marcucci, chief executive officer of Kedrion. “Based on our collective expertise in plasma-derived protein therapeutics, we believe Kedrion and Kamada are uniquely positioned to develop, manufacture and supply, in a relatively short period of time, an Anti-SARs-COV-2 IgG treatment.”
Kamada’s Chief Executive Officer, Amir London, said his company intends to begin clinical manufacturing shortly.
“I am confident that the collaboration with Kedrion, a global leader in plasma collection and plasma-derived therapeutics, will allow us to speed up the development of the product and strengthen our international reach,” he added.
The partners have an existing strategic supply and distribution agreement for KEDRAB, a plasma-derived FDA-approved human rabies immune globulin that was launched in the US in April 2018.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance